{"filings":[{"id":2243716,"accession_number":"0001193125-26-349107","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2026-08-13T20:00:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Q2 net loss $65.6M; DAYBREAK topline due Sept 2026, cash into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 net loss $65.6M ($1.05/sh) vs $54.3M ($1.03/sh) in Q2 2025; SBC $11.6M.","Cash and equivalents $125.9M at June 30, 2026; expected to fund operations into 2027.","R&D expense $56.1M (up from $42.8M) on PEAK/PINNACLE and manufacturing; G&A $10.8M.","Phase 3 DAYBREAK topline (Zenkuda/KSI-501, wet AMD) expected Sept 2026; PEAK Pivotal Analysis 1 (KSI-101, MESI) Dec 2026.","Enrollment completed for first 300-patient PEAK cohort; ALTO Phase 3 (KSI-501 vs aflibercept, DME) patient enrollment initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":863518,"accession_number":"0001193125-26-257766","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2026-06-04T21:22:02+00:00","items":["5.07"],"status":"ready","headline":"Kodiak Sciences annual meeting elects three directors, approves say-on-pay, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class II director nominees elected: Bancroft with 38.9M for, Dahiyat with 48.8M, Yang with 49.2M.","Advisory vote on executive compensation passed with 49.2M for, 323K against, 21K abstain.","Ratification of PricewaterhouseCoopers as auditor for FY2026 approved with 54.7M for, 53K against.","Proxies representing 88.53% of outstanding shares (55.0M shares) voted at the meeting.","No other proposals or contentious items; all standard annual meeting business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93014,"accession_number":"0001193125-26-211811","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences reports Q1 net loss $0.94/sh; Zenkuda GLOW2 positive, BLA planned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $169.5M as of March 31, 2026, expected to fund operations into 2027.","Net loss $58.2M ($0.94/sh) vs. $57.5M ($1.09/sh) in Q1 2025.","Zenkuda GLOW2: 62.5% ≥2-step DRSS improvement vs. 3.3% sham (p<0.0001); no vasculitis.","DAYBREAK Phase 3 topline in wet AMD September 2026; PEAK topline in MESI 4Q 2026.","R&D expenses rose to $48.5M from $43.6M driven by PEAK/PINNACLE and DAYBREAK studies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104292,"accession_number":"0001193125-26-134854","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak reports positive Phase 3 GLOW2 data for Zenkuda; plans accelerated BLA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zenkuda Phase 3 GLOW2: 62.5% vs 3.3% achieved ≥2-step DRSS improvement (p<0.0001).","85% risk reduction in sight-threatening complications (2.4% vs 15.8%, p=0.0001); no intraocular inflammation.","DAYBREAK Phase 3 wet AMD study fully enrolled (690 subjects); topline expected Sept 2026.","Q4 2025 net loss $56.7M ($1.04/shr); cash $209.9M; Dec 2025 equity raise net $173M.","KSI-101 Phase 3 PEAK topline 4Q2026, PINNACLE 2Q2027; Phase 1b APEX data showed robust responses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104291,"accession_number":"0001193125-26-127041","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GLOW2 Phase 3 positive: Zenkuda meets primary endpoint, 62.5% vs 3.3% DRSS improvement, BLA accelerated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["62.5% of Zenkuda patients achieved ≥2-step DRSS improvement vs 3.3% sham (p<0.0001).","85% risk reduction in sight-threatening complications (2.4% vs 15.8%, p=0.0001); 13.7% had ≥3-step DRSS improvement vs 0% sham.","Zenkuda well-tolerated: 0% intraocular inflammation, low cataract rate (2.3% vs 1.6%).","Efficacy independent of GLP-1 use: 60.0% with GLP-1 vs 64.3% without GLP-1.","Kodiak intends to accelerate BLA for Zenkuda; KSI-501 (wet AMD) readout 3Q2026, KSI-101 (MESI) 4Q2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120587,"accession_number":"0001193125-25-324882","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kodiak Sciences completes $184M public offering of 8M shares at $23/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters exercised in full the option for 1,043,478 additional shares, totaling 8,000,000 shares sold.","Gross proceeds to Kodiak were approximately $184 million before underwriting discounts and expenses.","Public offering price set at $23.00 per share; underwriters paid $21.62 per share.","Underwriting agreement signed Dec 16, 2025; offering closed Dec 18, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120586,"accession_number":"0001193125-25-280125","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q3 net loss $61.5M ($1.16/share); cash $72M; Phase 3 trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $61.5M ($1.16/sh) vs $43.9M ($0.84/sh) in Q3 2024; R&D expenses rose to $50.5M from $31.9M on higher clinical and manufacturing activity.","Cash and equivalents $72.0M as of Sept 30, 2025, down from prior quarter given ongoing Phase 3 spend.","Phase 1b APEX (KSI-101) showed ≥90% of patients in top doses achieved absence of retinal fluid; Phase 3 PEAK/PINNACLE enrolling faster than expected.","Phase 3 DAYBREAK (tarcocimab/KSI-501) in wet AMD completed enrollment of ~690 patients; topline data expected 3Q 2026.","Upcoming catalysts: GLOW2 topline 1Q 2026; KSI 101 Phase 3 topline 4Q 2026/1Q 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137186,"accession_number":"0000950170-25-107982","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q2 net loss $54.3M, cash $104.2M; pipeline milestones on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $54.3M ($1.03/share) vs $45.1M loss a year ago; R&D expenses rose to $42.8M.","Cash and equivalents $104.2M; expected to fund operations into 2026.","Tarcocimab Phase 3 GLOW2 topline data expected Q1 2026; DAYBREAK (wet AMD) topline in Q3 2026.","KSI-101 Phase 1b MESI data: half of patients ≥15 letter gain at Week 12; Phase 3 enrolling.","Investor R&D Day on July 16, 2025 presented 12-week KSI-101 data and commercial strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154473,"accession_number":"0001193125-25-134149","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kodiak Sciences stockholders elect directors and ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Richard S. Levy, M.D. (29.2M for, 8.4M withheld) and Robert A. Profusek, J.D. (24.7M for, 12.9M withheld) as Class I directors.","Advisory vote on named executive officer compensation approved: 35.2M for, 2.4M against, 49k abstain.","Ratification of PricewaterhouseCoopers as auditor for FY2025 passed: 43.0M for, 36k against.","Total shares voted: 43.4M (82.2% of eligible shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154472,"accession_number":"0000950170-25-071474","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q1 net loss $57.5M ($1.09/shr), cash $138.9M; pipeline on track for 2026 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $57.5M ($1.09/shr) vs $43.0M ($0.82) in Q1 2024; non-cash stock comp $15.9M.","Cash and cash equivalents $138.9M; company believes current cash funds operations into 2026.","R&D expenses $43.6M, up from $29.9M YoY, driven by increased clinical and manufacturing activities.","Phase 3 GLOW2 (DR), DAYBREAK (wet AMD) for tarcocimab and KSI-501; Phase 1b APEX data for KSI-101 expected.","Investor R&D Update scheduled for July 16, 2025; topline data targeted in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173031,"accession_number":"0000950170-25-046067","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences reports Q4 net loss of $44.1M, cash $168.1M; pipeline trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $168.1M at Dec 31, 2024; expected to fund operations into 2026.","Q4 2024 net loss $44.1M ($0.84/sh) vs $59.5M ($1.13/sh) in Q4 2023; R&D expenses $31.8M.","Tarcocimab Phase 3 GLOW2 (diabetic retinopathy) enrollment complete; topline data targeted 1Q2026.","Tarcocimab & KSI-501 Phase 3 DAYBREAK (wet AMD) enrollment complete; topline data targeted 2Q2026.","KSI-101 granted FDA Orphan Drug Designation; pivotal study initiation expected 2Q2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190055,"accession_number":"0000950170-24-127029","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q3 net loss $43.9M, cash $197.9M; provides pipeline updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $43.9M ($0.84/sh) vs $50.0M ($0.95/sh) in Q3 2023; cash $197.9M expected to fund operations into 2026.","Phase 3 GLOW2 (diabetic retinopathy) and DAYBREAK (wet AMD) enrolling; enrollment completion targeted H1 2025.","KSI-101 APEX study enrolling; dose selection for pivotal studies expected Q2 2025.","Tarcocimab ocular half-life 20 days (3x faricimab, 2-3x aflibercept) presented at Sept R&D Day.","Preclinical ABCD pipeline expanded to glaucoma and geographic atrophy programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206553,"accession_number":"0000950170-24-096985","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q2 net loss $45.1M, cash $219.2M; three Phase  trials enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $45.1M ($0.86/sh) vs $80.2M ($1.53/sh) in Q2 2023; R&D expense down 52% to $32.5M.","Cash and cash equivalents $219.2M; company believes funds operations into 2026.","Phase 3 GLOW2 (diabetic retinopathy) and DAYBREAK (wet AMD) actively enrolling; Phase 1b APEX (KSI-101) enrolling.","Appointed Dolly Chang (ex-Genentech) as CSO; promoted Almas Qudrat (CQO), Wayne To (CTO), Pablo Velazquez-Martin (CMO).","Investor Day scheduled for September 23, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223726,"accession_number":"0001193125-24-156056","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kodiak Sciences annual meeting results: Felix Baker receives ~32% withheld votes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Felix J. Baker re-elected with 27,555,597 for, 13,043,671 withheld (~32% of votes cast against).","Victor Perlroth re-elected with 39,408,580 for, 1,466,194 withheld.","Advisory executive compensation approved: 36,430,878 for, 4,405,093 against (~89% support).","Ratification of PricewaterhouseCoopers as auditor: 44,168,820 for, 65,022 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223725,"accession_number":"0000950170-24-060455","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q1 net loss $43M, cash $245.9M; advances tarcocimab and KSI-101 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $43.0M ($0.82 per share) vs $70.8M ($1.35) in Q1 2023; includes $18.4M stock-based compensation.","Cash and equivalents $245.9M; company expects runway into 2026.","R&D expenses $29.9M, down from $56.5M YoY due to reduced tarcocimab clinical activities.","GLOW2 Phase 3 diabetic retinopathy study actively enrolling; DAYBREAK wet AMD study activation targeted mid-2024.","Phase 1b APEX study of KSI-101 (anti-IL-6/VEGF-trap) in macular edema expected to start enrollment in June 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243137,"accession_number":"0000950170-24-037608","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences reports Q4 net loss of $59.5M; outlines Phase 3 plans for tarcocimab and KSI-501","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $59.5M ($1.13/share) vs $70.4M ($1.35/share) in Q4 2022; R&D expenses fell to $46.6M.","Cash and equivalents $285.5M; company believes sufficient to fund operations into 2026.","Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively enrolling; uses go-to-market formulation.","Phase 3 DAYBREAK study in wet AMD (KSI-501 vs tarcocimab vs aflibercept) targeted to start mid-2024 after FDA discussions.","Phase 1b study of KSI-101 planned for Q2 2024; dual pivotal studies targeted for later 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260525,"accession_number":"0000950170-23-063701","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q3 net loss $50M; GLOW study shows tarcocimab 29-fold improvement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $50.0M ($0.95/shr) vs $77.0M ($1.47) in Q3 2022; cash $345.7M.","R&D expenses fell to $36.2M from $61.7M due to development pause and forfeitures.","GLOW phase 3: 41.1% tarcocimab patients had ≥2-step DRSS improvement vs 1.4% sham (p<0.0001).","89% risk reduction in sight-threatening complications; plan to reboot tarcocimab for single BLA.","KSI-501 phase 1 enrollment complete; data expected Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260524,"accession_number":"0000950170-23-058996","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kodiak Phase 3 GLOW NPDR study meets primary endpoint; plans to resume tarcocimab","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GLOW met primary endpoint: 41.1% vs 1.4% achieved >=2-step DRSS improvement (p<0.0001).","Sight-threatening complications risk reduced 89%: 2.3% vs 21.0% (p<0.0001).","DME development risk reduced 95%: 0.7% tarcocimab vs 13.7% sham.","Kodiak pauses then resumes tarcocimab; plans one additional pivotal study for single BLA for wAMD, RVO, NPDR.","Serious ocular adverse events and intraocular inflammation rates similar between groups."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277829,"accession_number":"0000950170-23-043277","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2023-08-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kodiak Sciences CMO and Chief Development Officer Dr. Jason Ehrlich resigns effective August 25, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resignation as Chief Medical Officer and Chief Development Officer effective August 25, 2023.","Resignation not due to any disagreement with the Company on operations, policies, or practices.","No successor named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277828,"accession_number":"0000950170-23-042419","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q2 net loss $80.2M; winds down tarcocimab after Phase 3 DME miss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 net loss $80.2M ($1.53/sh) vs $90.6M ($1.74/sh) in Q2 2022.","Cash and equivalents $378.7M at June 30, 2023.","Phase 3 GLEAM and GLIMMER in DME missed primary efficacy endpoint; tarcocimab studies being wound down.","Phase 3 DAYLIGHT in wet AMD met endpoint; no cataract imbalance observed.","KSI-501 Phase 1 enrollment completed; exploring both unconjugated protein and bioconjugate forms."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277827,"accession_number":"0000950170-23-033933","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Kodiak discontinues tarcocimab after Phase 3 DME studies fail to meet endpoints; DAYLIGHT meets primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $379M as of June 30, 2023 (unaudited).","DAYLIGHT study in wet AMD met primary endpoint of non‑inferior visual acuity gains vs aflibercept.","GLEAM and GLIMMER DME studies did not meet primary efficacy endpoint; tarcocimab letters gained 6.4 vs 10.3 (GLEAM) and 7.4 vs 12.2 (GLIMMER).","Cataract adverse events at 19% on tarcocimab vs 9% on aflibercept in pooled DME safety population; no vasculitis or occlusion.","Company discontinues further development of tarcocimab based on these data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295823,"accession_number":"0001193125-23-162502","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kodiak Sciences stockholders elect three Class II directors, approve executive compensation, ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Charles A. Bancroft, Bassil I. Dahiyat, and Taiyin Yang as Class II directors with >77% votes for each.","Advisory vote on named executive officer compensation approved: 32.5M for, 5.3M against, 43K abstain.","Ratification of PricewaterhouseCoopers as auditor: 41.4M for, 29K against, 355K abstain.","Proxies representing 41.78M shares (79.82% of eligible) voted at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295822,"accession_number":"0000950170-23-022193","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q1 2023 net loss $70.8M; four Phase 3 readouts expected in Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash position $421.2M; net loss $70.8M ($1.35/share) vs $95.7M ($1.83/share) Q1 2022.","R&D expenses $56.5M (down from $76.2M) due to maturation of tarcocimab program and manufacturing timing.","Topline data for GLEAM, GLIMMER, DAYLIGHT studies expected July 2023; GLOW study expected September 2023.","BEACON Phase 3 study met primary endpoint in 2022; company plans single BLA for tarcocimab if successful.","Phase 1 dosing started for KSI-501 bispecific antibody biopolymer conjugate in DME."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316360,"accession_number":"0000950170-23-010303","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q4 net loss $70.4M ($1.35/sh); cash $478.9M; tarcocimab data Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities totaled $478.9M at Dec 31, 2022.","Q4 2022 net loss $70.4M ($1.35/sh) vs Q4 2021 net loss $93.2M ($1.79/sh).","R&D expenses $56.0M in Q4 2022, down from $75.6M; G&A $18.1M vs $17.5M.","Topline data from 4 Phase 3 tarcocimab studies (DME, NPDR, wAMD) expected Q3 2023.","KSI-501 Phase 1 in DME screening patients; commercial cGMP manufacturing started at Ursus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334640,"accession_number":"0000950170-22-023842","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q3 net loss $77M; cash $537M; Ph3 trials on track for 2023 readouts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $77.0M ($1.47/sh) vs $67.5M ($1.30) in Q3 2021; increase driven by stock-based compensation.","Cash, cash equivalents and marketable securities of $537.4M; includes $2.5M unrealized loss from interest rates.","R&D expenses $61.7M (up from $56.0M) and G&A $17.8M (up from $11.5M) both primarily due to non-cash stock comp.","Four Phase 3 trials (GLEAM/GLIMMER DME, DAYLIGHT wet AMD, GLOW NPDR) expected to report topline data in 2023.","KSI-501 IND filing on track for Q4 2022; Phase 1 study expected to begin early 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352066,"accession_number":"0000950170-22-016130","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q2 net loss $90.6M; BEACON Phase 3 RVO study meets endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $90.6M ($1.74/share) vs $55.9M ($1.08/share) in Q2 2021 driven by higher R&D and stock-based comp.","Cash and equivalents $597.9M at quarter-end, down from prior quarter but sufficient for operations.","BEACON study in RVO met primary endpoint: tarcocimab every 8 weeks non-inferior to aflibercept monthly.","Phase 3 DME studies GLEAM/GLIMMER and wet AMD study DAYLIGHT fully enrolled; topline data expected mid-2023.","Plans to file single BLA for tarcocimab across all indications if Phase 3 data are positive."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352065,"accession_number":"0000950170-22-015232","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kodiak Sciences: BEACON Phase 3 tarcocimab meets primary endpoint in retinal vein occlusion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BEACON Phase 3 randomized 568 RVO patients to tarcocimab 5 mg q8w after 2 monthly loads vs aflibercept 2 mg q4w.","Primary endpoint of non-inferior BCVA change at week 24 met in BRVO (p=0.0004) and overall RVO (p=0.0243).","Tarcocimab dosed 4 times vs aflibercept 6 times in first 24 weeks, showing extended durability.","Safety favorable: low intraocular inflammation (1.4% vs 0.4%); no vasculitis or retinal artery occlusion.","Full primary results to be presented at ophthalmology congresses in September 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369551,"accession_number":"0001193125-22-169440","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2022-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kodiak Sciences reports 2022 annual meeting voting results; all proposals pass","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["42,377,902 shares (81.6% of eligible) present at June 7, 2022 annual meeting.","Class I directors elected: Richard S. Levy with 27,340,469 for; Robert A. Profusek with 25,656,888 for.","Advisory say-on-pay approved: 32,519,426 for, 3,748,425 against, 31,564 abstain.","Ratification of PwC as auditor for FY2022: 42,314,554 for, 30,677 against, 32,671 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369550,"accession_number":"0000950170-22-008988","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q1 net loss $95.7M ($1.83/share); updates KSI-301 program after Ph2b/3 miss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $95.7M ($1.83/share) vs $50.4M ($0.98/share) in Q1 2021.","R&D expenses $76.2M, up 89% YoY; G&A $19.6M, up 92% YoY; cash $671.7M.","KSI-301 Phase 2b/3 wet AMD missed primary endpoint; ongoing Phase 3 studies modified to reduce undertreatment risk.","BEACON top-line data expected August 2022; DAYLIGHT, GLEAM, GLIMMER data mid-2023.","Commercial manufacturing facility in Visp, Switzerland reached mechanical completion March 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388693,"accession_number":"0000950170-22-002538","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q4 net loss $93.2M; wet AMD pivotal trial misses primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2b/3 KSI-301 study in wet AMD did not meet non-inferiority vs aflibercept for extended dosing.","59% of KSI-301 patients achieved 5-month dosing; safety profile acceptable with no new signals.","Q4 net loss $93.2M ($1.79/share) vs $46.6M a year ago; full year net loss $267.0M.","R&D expenses $75.6M in Q4, up from $37.4M, driven by clinical trial and manufacturing costs.","Cash and equivalents $731.5M; BEACON RVO top-line data expected Q3 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388692,"accession_number":"0000950170-22-001684","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2022-02-23T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Kodiak Sciences: KSI-301 fails primary endpoint in wet AMD Phase 2b/3 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint not met: KSI-301 failed to show non-inferior visual acuity gains vs aflibercept in wet AMD.","Cash and cash equivalents at Dec 31, 2021 were approximately $731.5M.","Pre-specified secondary analysis: 59% of KSI-301 patients achieved 5-month dosing with comparable visual acuity and anatomic improvements.","Safety: KSI-301 generally safe; intraocular inflammation in 3.2% vs 0% for aflibercept; all resolved.","Trial randomized 559 participants, ~80% in US; flexible long-interval regimen for KSI-301 vs fixed 2-month for aflibercept."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406642,"accession_number":"0000950170-21-003772","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Q3 net loss $67.5M ($1.30/shr); cash $799M; pipeline on track for 2022 readouts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $67.5M ($1.30/shr) from $36.1M ($0.80/shr) in Q3 2020.","R&D expenses rose to $56.0M (vs $29.3M) on KSI-301 trial and manufacturing costs.","Cash and equivalents $799.2M; no revenue reported.","DAZZLE (wet AMD) topline data expected Q1 2022; BEACON (RVO) mid-2022.","GLEAM/GLIMMER (DME) enrollment target Q1 2022; DAYLIGHT (wet AMD) enrollment 1H 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406641,"accession_number":"0001193125-21-300175","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2021-10-15T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Kodiak shareholders approve 5.5M-share long-term incentive plan for executives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders voted 77% in favor (Bylaws Standard) to approve the 2021 Long-Term Performance Incentive Plan.","Plan reserves 5,502,334 shares; CEO Perlroth receives 2.18M options, CFO Borgeson and CMO Ehrlich each 500K.","Performance vesting tied to 7 stock price tranches ($200-$800/share) and operational milestones (BLA approvals, $2.5B sales).","Exercise price set at $88.21/share, 10-year term, with a 7-year performance period ending August 2028.","Eligible participants (Grade 10+ employees) forgo a portion of annual long-term awards in exchange for these options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425633,"accession_number":"0000950170-21-001601","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2021-09-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kodiak Sciences unveils 7-year performance stock option plan tied to share price milestones up to $800","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NEOs and eligible employees may forgo up to 75% of annual equity awards for 7 years in exchange for one-time performance stock options.","Options vest in tranches upon achieving stock price milestones: $200/share first, then $100 increments up to $800 (≈$50B market cap).","Operational milestones include FDA approval of KSI-301 in wet AMD, DME, RVO and fiscal-year sales >$2.5B.","90% of eligible employees opted in; awards conditional on stockholder approval at special meeting in October 2021.","Participants are economically worse-off below $400/share compared to continuing annual awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425632,"accession_number":"0000950170-21-001072","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2021-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kodiak Sciences Q2 net loss widens to $55.9M; KSI-301 trials on track for data in early 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $55.9M ($1.08/share) vs $26.0M ($0.58) in Q2 2020; R&D expenses rose to $45.4M.","Cash and equivalents $880.9M; royalty financing from BBA capped at $450M after second $125M tranche not paid.","Phase 3 wet AMD DAZZLE study on track topline data Q1 2022; enrollment in BEACON, GLEAM, GLIMMER, DAYLIGHT ongoing.","China IND approved for KSI-301 in RVO and DME; first patients expected in 2021.","Proposed INN for KSI-301 is tarcocimab tedromer; GLOW study in non-proliferative DR to start August 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425631,"accession_number":"0000950170-21-000510","cik":1468748,"company_name":"Kodiak Sciences Inc.","ticker":"KOD","form_type":"8-K","filed_at":"2021-07-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Kodiak Sciences avoids $125M royalty-draw; reduces royalty cap to $450M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company and BBA agreed not to fund second $125M tranche of royalty financing agreement.","Royalty cap reduced from $1,012.5M to $450M (4.5x the $100M already funded).","Decision driven by strong balance sheet after $612M capital raise in Nov 2020 and clinical progress.","Independent board committee ratified the decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2264713812.0815043,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}